Nab-paclitaxel-based induction therapy, chemotherapy and re-irradiation for head and neck cancer

Share it with your friends Like

Thanks! Share it with your friends!


Ari Rosenberg, MD, University of Chicago Medical Center, Chicago, IL, discusses the Phase I trial (NCT01847326) of nab-paclitaxel-based induction therapy followed by nab-paclitaxel-based chemotherapy and re-irradiation for patients with previously-treated head and neck cancer. The primary endpoints were maximum dosage and dose-limiting toxicity of nab-paclitaxel when combined with the FHX regimen (5-fluorouracil, hydroxyurea, and twice-daily radiation). Secondary endpoints were progression-free survival (PFS) and overall survival (OS). The recommended Phase II dosage was determined to be 100mg/m2. 23% of patients saw a 4-year PFS and 26% achieved OS. The PFS and OS rates were higher in patients responding to induction chemotherapy and were then treated with chemo-irradiation. This interview took place at the European Society for Medical Oncology (ESMO) 2021 congress.


Write a comment